While Global Strategy sets the initial direction, true agility is sustained through a 360-degree loop that prioritises ...

The drug acts as a prostacyclin receptor agonist, which is a fairly crowded class with several approved oral, intravenous or ...

uniQure held a Type A meeting with the FDA at the end of January and, in a statement released today, said the agency "cannot agree that data from the Phase I/II studies, compared to an external ...

Novo Nordisk has said it will invest DKK 3.2 billion (€432 million) in a manufacturing plant in Ireland that will be used to ...

Roche's oral BTK inhibitor fenebrutinib has hit the spot in the final trial in its phase 3 programme, in relapsing multiple sclerosis (RMS), and is now being prepared for regulatory filings.

Recent transactions make clear that large pharmaceutical companies now view rare disease as a core area for sustained growth, rather than episodic deal-making. BioMarin’s acquisition of Amicus ...

Specifically, the CHMP has backed conditional marketing authorisation for Ojemda (tovorafenib) as a monotherapy for children ...

Atrium is led by Kathleen Gallagher, who was chief programme officer at Avidity before it was acquired by Novartis and will ...